{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:01:36Z","timestamp":1793916096949,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172043"],"award-info":[{"award-number":["82172043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202273"],"award-info":[{"award-number":["82202273"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Plan on Enhancing Scientific Research in GMU","award":["GMUCR2024-02002"],"award-info":[{"award-number":["GMUCR2024-02002"]}]},{"name":"Plan on Enhancing Scientific Research in GMU","award":["2023.198"],"award-info":[{"award-number":["2023.198"]}]},{"name":"Innovative Clinical Technique of Guangzhou"},{"name":"Featured Clinical Technique of Guangzhou"},{"name":"Clinical Study Project of the Second Affiliated Hospital, Guangzhou Medical University","award":["2021-LCYJ-DZX-01"],"award-info":[{"award-number":["2021-LCYJ-DZX-01"]}]},{"name":"Clinical Study Project of the Second Affiliated Hospital, Guangzhou Medical University","award":["2022-LCYJ-YY-02"],"award-info":[{"award-number":["2022-LCYJ-YY-02"]}]},{"name":"Guangzhou School (College) Enterprise Joint Funding Project","award":["SL2023A03J00463"],"award-info":[{"award-number":["SL2023A03J00463"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for advanced HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a single-center, single-arm phase II trial recruiting patients with BCLC stage C HCC. A safety run-in cohort was planned with the first 6 patients receiving oral donafenib 200\u00a0mg twice daily and intravenous sintilimab 200\u00a0mg once every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated to determine the recommended dose of donafenib for those enrolled thereafter. The primary endpoint of this study was progression-free survival (PFS) per mRECIST.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>30 patients were enrolled. As 3 patients (50.0%) experienced DLTs during safety run-in, the initial dose of donafenib was adjusted to 200\u00a0mg once daily for subsequent patients. The primary endpoint was met with a median PFS of 6.2 (95% confidence interval [CI], 4.4-8.0) months per mRECIST (6.3 [95% CI, 5.4\u20137.2] months per RECIST 1.1). The objective response rate was 23.3% per mRECIST and 16.7% per RECIST 1.1, while the disease control rate reached 76.7% per mRECIST\/RECIST 1.1. The median overall survival was 16.0 (95% CI, 13.5\u201318.5) months. Treatment-related adverse events (TRAEs) occurred in 28 patients (93.3%) and grade 3 TRAEs were observed in 9 patients (30.0%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Don-Sin showed promising antitumor effects with an acceptable safety profile in patients with advanced stage HCC. The preliminary findings need to be further evaluated in phase III randomized controlled trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov (identifier: NCT05162352; date of registration: December 4, 2021).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13605-2","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:02:22Z","timestamp":1738756942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoyang","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangshun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liteng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaozhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"issue":"5","key":"13605_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(5):541\u201365.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"13605_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682\u2013720.","journal-title":"Liver Cancer"},{"issue":"1","key":"13605_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"3","key":"13605_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00280-020-04031-1","volume":"85","author":"X Li","year":"2020","unstructured":"Li X, Qiu M, Wang S, Zhu H, Feng B, Zheng L. A phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2020;85(3):593\u2013604.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"13605_CR5","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib Versus Sorafenib in First-Line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, Open-Label, parallel-controlled phase II-III trial. J Clin Oncol. 2021;39(27):3002\u201311.","journal-title":"J Clin Oncol"},{"issue":"5","key":"13605_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. Guidelines for the diagnosis and treatment of primary Liver Cancer (2022 Edition). Liver Cancer. 2023;12(5):405\u201344.","journal-title":"Liver Cancer"},{"issue":"3","key":"13605_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"13605_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"AL Cheng","year":"2020","unstructured":"Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72(2):307\u201319.","journal-title":"J Hepatol"},{"issue":"7","key":"13605_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","volume":"22","author":"PR Galle","year":"2021","unstructured":"Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(7):991\u20131001.","journal-title":"Lancet Oncol"},{"issue":"7","key":"13605_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"issue":"12","key":"13605_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus Pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"10408","key":"13605_CR12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus Rivoceranib versus Sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346.","journal-title":"Lancet"},{"issue":"26","key":"13605_CR13","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase ib study of Lenvatinib Plus Pembrolizumab in patients with Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"13605_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.2020.38.4_suppl.513","volume":"38","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ikeda M, Motomura K, Okusaka T, Kobayashi M. A phase ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117. J Clin Oncol. 2020;38(Suppl 4):513.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13605_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of Hepatocellular Carcinoma in Japan: JSH Consensus statements and recommendations 2021 Update. Liver Cancer. 2021;10(3):181\u2013223.","journal-title":"Liver Cancer"},{"key":"13605_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001819","author":"M Cai","year":"2024","unstructured":"Cai M, Liang L, Zhang J, Chen N, Huang W, Guo Y, et al. Lenvatinib plus drug-eluting bead transarterial chemoembolization with\/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Int J Surg. 2024;110(12):7860-70. https:\/\/doi.org\/10.1097\/JS9.0000000000001819","journal-title":"Int J Surg"},{"issue":"8","key":"13605_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","volume":"8","author":"M Pinter","year":"2023","unstructured":"Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 2023;8(8):760\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"13605_CR18","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1186\/s12885-023-11485-y","volume":"23","author":"K Wang","year":"2023","unstructured":"Wang K, Xiang YJ, Yu HM, Cheng YQ, Feng JK, Liu ZH, et al. Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation. BMC Cancer. 2023;23(1):1017.","journal-title":"BMC Cancer"},{"issue":"4","key":"13605_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/liv.15831","volume":"44","author":"M Cai","year":"2024","unstructured":"Cai M, Huang W, Liang W, Guo Y, Liang L, Lin L, et al. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: a phase II study. Liver Int. 2024;44(4):920\u201330.","journal-title":"Liver Int"},{"key":"13605_CR20","doi-asserted-by":"publisher","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","volume":"13","author":"M Cai","year":"2022","unstructured":"Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, et al. Transarterial Chemoembolization Combined with Lenvatinib Plus PD-1 inhibitor for Advanced Hepatocellular Carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387.","journal-title":"Front Immunol"},{"key":"13605_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/JHC.S353956","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, et al. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line treatment for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study. J Hepatocell Carcinoma. 2022;9:157\u201370.","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"13605_CR22","doi-asserted-by":"publisher","first-page":"e0054","DOI":"10.1097\/HC9.0000000000000054","volume":"7","author":"C Guo","year":"2023","unstructured":"Guo C, Zhang J, Huang X, Chen Y, Sheng J, Huang X, et al. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: a phase II trial. Hepatol Commun. 2023;7(3):e0054.","journal-title":"Hepatol Commun"},{"issue":"4","key":"13605_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","volume":"80","author":"M Zhu","year":"2024","unstructured":"Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a multicenter, single-arm, phase 2 study. Hepatology. 2024;80(4):807\u201315.","journal-title":"Hepatology"},{"issue":"31","key":"13605_CR24","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","volume":"35","author":"KA Reiss","year":"2017","unstructured":"Reiss KA, Yu S, Mamtani R, Mehta R, D\u2019Addeo K, Wileyto EP, et al. Starting dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: a Retrospective, multi-institutional study. J Clin Oncol. 2017;35(31):3575\u201381.","journal-title":"J Clin Oncol"},{"issue":"14","key":"13605_CR25","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1002\/cam4.3228","volume":"9","author":"MA Alghamdi","year":"2020","unstructured":"Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi H, Chan KK, et al. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: results from a Canadian Multicenter Database. Cancer Med. 2020;9(14):4918\u201328.","journal-title":"Cancer Med"},{"issue":"1","key":"13605_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12929-024-01011-y","volume":"31","author":"V Chew","year":"2024","unstructured":"Chew V, Chuang CH, Hsu C. Translational research on drug development and biomarker discovery for hepatocellular carcinoma. J Biomed Sci. 2024;31(1):22.","journal-title":"J Biomed Sci"},{"issue":"4","key":"13605_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C. Immunomodulatory effects of current targeted therapies on Hepatocellular Carcinoma: implication for the future of Immunotherapy. Semin Liver Dis. 2018;38(4):379\u201388.","journal-title":"Semin Liver Dis"},{"issue":"10","key":"13605_CR28","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","volume":"73","author":"Y Huang","year":"2013","unstructured":"Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"13605_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol. 2020;72(2):320\u201341.","journal-title":"J Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13605-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13605-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T12:02:42Z","timestamp":1738756962000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13605-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13605"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13605-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital, Guangzhou Medical University (approval number, 2021-hs-68). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration. Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}